A non-anticoagulant heterofucan has antithrombotic activity in vivo.
Fucan is a term used to denominate a family of sulfated L-fucose-rich polysaccharides. The brown alga Spatoglossum schröederi (Dictyotaceae) has three heterofucans namely fucan A, B and C. The 21 kDa fucan A is composed of a core of a beta (1-3) glucuronic acid-containing oligosaccharide of 4.5 kDa with branches at C4 of the fucose chains alpha (1-3) linked. The fucose is mostly substituted at C4 with a sulfate group and at C2 with chains of beta (1-4) xylose. This fucan has neither anticoagulant (from from 0.1 to 100 microg) nor hemorrhagic activities (from 50 to 800 microg/mL). The antithrombotic test in vivo showed that fucan A has no activity in any of the concentrations (from 0.2 to 20 microg/g/day) tested 1 h after polysaccharide administration. However, when fucan A was injected endovenously 24 h before the ligature of the venae cavae, we observed a dose-dependent effect, reaching saturation at around 20 microg/g of rat weight. In addition, this effect is also time-dependent, reaching saturation around 16 h after fucan administration. In addition, regardless of the administration route, fucan A displayed antithrombotic activity. The exception was the oral pathway. Of particular importance was the finding that fucan A stimulates the synthesis of an antithrombotic heparan sulfate from endothelial cells like heparin. The hypothesis has been raised that the in vivo antithrombotic activity of fucan A is related to the increased production of this heparan. Taken together with the fact that the compound is practically devoid of anticoagulant and hemorrhagic activity, the data suggest that it may be an ideal antithrombotic agent in vivo.
Barroso
Edjane M A
EM
Programa de Pós-graduação em Ciências da Saúde, Departamento de Bioquímica, Universidade Federal do Rio Grande do Norte-UFRN, Natal-RN, Brazil.
Costa
Leandro S
LS
Medeiros
Valquíria P
VP
Cordeiro
Sara L
SL
Costa
Mariana S S P
MS
Franco
Célia R C
CR
Nader
Helena B
HB
Leite
Edda L
EL
Rocha
Hugo A O
HA
D000818:Animals; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D042783:Endothelial Cells / Q000187:drug effects* / Q000378:metabolism; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000302:isolation & purification*; D006497:Heparan Sulfate / Q000096:biosynthesis*; D006801:Humans; D008297:Male; D000459:Phaeophyceae / Q000737:chemistry*; D011134:Polysaccharides / Q000009:adverse effects / Q000302:isolation & purification*; D011817:Rabbits; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
D005343:Fibrinolytic Agents; D006497:Heparan Sulfate; D011134:Polysaccharides; C007789:fucoidan